NMR metabolomic analysis for "in vivo" studies

Thanks to the new partnership with MTTlab we can assist our clients in delivering both in vitro and in vivo data sets for the preclinical evaluation of investigational compounds which can be used for regulatory submissions, project evaluation, scientific publications and fund raising. MTTlab specializes in toxicology and efficacy testing of novel oncological compounds.

The new collaboration allows us to offer state of the art NMR metabolomic analysis in all in vivo studies.

The combination of top-level technology and expertise from both fields offered by MTTlab and Giotto Biotech has been streamlined into an integrated workflow process that goes beyond the sum of its parts and provides significant advantages to clients. The resulting turn-key service was designed so that the client need only send the drug candidate or lead compound and provide a set of relevant information. A toxicity and/or efficacy study on an appropriate animal model will then be performed with the relevant end-point readouts (including biochemical, histopathological and metabolomics analyses). A final report will be provided at the end of each study in a standardized format.

Some examples of what we can offer:

1.      Design of a protocol to monitor potential toxicity of a newly developed drug candidate - on the whole organism and specific organs during and at the study end-point.

A study would consist of a minimum of three groups of animals (control, low dose and high dose group) from which body fluids are collected to establish metabolomic profiles. At the end of the study histopathology samples are analysed, biochemical blood analysis is performed and blood and organ metabolomic profiles are established.
As there is a correlation between extracellular metabolites and intracellular situation, the analysis of metabolomic profiles of either body fluid samples or organs can provide information on organ- specific toxicity and an insight into a drug‘s mode of action. Since body fluid sampling is non-invasive, a large quantity of data can be obtained during the course of a toxicology study and not only at the study end-point.

2.      Design of a protocol to test the efficacy of a newly developed drug candidate.

We will assist with the animal model selection, based on the putative mode of action and expected effect.
The drug candidate effect is monitored during the whole study. Body fluids are collected at defined time-points which are then used to establish metabolomic profiles.
At the study pre-defined end-point, a pathology report is prepared is prepared pathology report, the metabolomic profiles of selected organs, tumors, and histopathology samples are analysed and a biochemistry blood analysis is performed analysed metabolomic profiles of selected organs and tumors, histopathology samples and performed biochemistry blood analysis. Metabolomics can be a valid support to identify and validate novel therapeutic targets, create alternative screening protocols, helping with the selection of cancer metabolite biomarkers, perform disease fingerprinting and identify metabolite signatures for the drug efficacy mechanism of action.

Main advantages of a metabolomic approach to in vivo studies:

  • high reproducibility
  • wide range of quantitative results
  • very well-suited for compound identification
  • metabolic pathway trackability
  • non-destructive technique